Public Consultation on the Post-market Review of PAH medicines
Page last updated: 25 May 2020
Consumer Session
A consumer session was held in Sydney on Saturday 14 October 2017 with members of the Pulmonary Hypertension Association Australia (PHAA) during their PHAA Members & Carers Day to provide further opportunities for consumers to contribute to the Review. The Consumer Outcome Statement is provided below:
- PAH Review Consumer Outcome Statement - (Word 57 KB)
- PAH Review Consumer Outcome Statement - (PDF 121 KB)
Public Consultation addressing the Terms of Reference: 13 February to 27 March 2017 (closed)
Public consultation addressing the Review and final Terms of Reference closed on 27 March 2017. The Department appreciates the contribution of all organisations and the individual who made a submission.
Public Consultation on the draft Terms of Reference: 2 May to 16 May 2016 (closed)
The public consultation process for the draft Terms of Reference closed on 16 May 2016. The Department appreciates the contribution of all organisations and individuals who made a submission.
Subscribe to news updates for the latest information regarding reviews, including public consultation opportunities.
Disclaimer
- The views expressed in submissions published on this website are solely those of the contributing authors or organisations.
- The Commonwealth accepts no responsibility for the completeness or accuracy of any information contained in the submissions.
- The Commonwealth makes no representations about the suitability of the information for any particular purpose. Users of the information must make their own inquiries and assessments about those matters or seek independent advice.
- Submissions are published on the understanding that the contributing authors or organisations have copyright in the submissions either by way of ownership or a licence. They retain their copyright, and by making submissions they licence the Commonwealth to publish the submissions, unless a party when making a submission has requested that it be kept confidential and the Commonwealth clearly agrees that the submission will be kept confidential.
Privacy
Unless otherwise requested, submissions commenting on the draft Terms of Reference have been published below.
The Department of Health does not publish submissions, or parts of submissions, which contain personal information, offensive language, potentially defamatory material or copyright infringing material.
Responsibility for copyright in submissions resides with the author(s), not with the Department of Health.
All submissions have been converted to Portable Document Format (PDF) for publication and may have a different appearance to the document that was submitted.
All submissions and contact details will be stored in accordance with the Privacy Act 1988 and the Archives Act 1983. Should you have any concerns about the storage of your submission, or if you wish to gain access to make a correction, please contact the Review’s Secretariat. A copy of the Department’s privacy policy is available on request. If you wish to make a complaint about the handling of your private information, you may contact the Department of Health Privacy Contact Officer and, if unsatisfied with the response, you may submit a complaint to the Office of the Australian Information Commissioner.
|
Submission |
Author Name |
Document Link |
Date Received |
|---|---|---|---|
|
1 |
Thoracic Society of Australia and New Zealand (TSANZ) |
21/03/2017 |
|
|
2 |
Industry Organisation |
Not for Publication |
29/05/2017 |
|
3 |
Industry Organisation |
Not for Publication |
27/03/2017 |
|
4 |
Pulmonary Hypertension Association Australia (PHA Australia) |
24/05/2017 |
|
|
5 |
GlaxoSmithKline Pty Ltd |
27/03/2017 |
|
|
6 |
Dr Kenneth Whyte |
28/03/2017 |
|
|
7 |
Council of Australian Therapeutic Advisory Groups (CATAG) |
29/05/2017 |
|
Submission |
Author Name |
Document Link |
Date Received |
|---|---|---|---|
|
1 |
Pulmonary Hypertension Society of Australia and New Zealand Inc (PHSANZ) |
13/05/2016 |
|
|
2 |
Academic / Health Professional |
Not for Publication |
14/05/2016 |
|
3 |
Individual |
Not for Publication |
15/05/2016 |
|
4 |
Individual |
Not for Publication |
15/05/2016 |
|
5 |
Actelion Pharmaceuticals Australia Pty Ltd |
16/05/2016 |
|
|
6 |
Individual |
Not for Publication |
16/05/2016 |
|
7 |
Individual |
Not for Publication |
16/05/2016 |
|
8 |
Dr Richard Whitaker |
16/05/2016 |
|
|
9 |
Lung Foundation Australia |
16/05/2016 |
|
|
10 |
Individual |
Not for Publication |
16/05/2016 |
|
11 |
Individual |
Not for Publication |
16/05/2016 |
|
12 |
GlaxoSmithKline Pty Ltd |
16/05/2016 |
|
|
13 |
PHA Australia Inc |
16/05/2016 |
|
|
14 |
Individual |
Not for Publication |
16/05/2016 |
